“Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 ”. 2022. SKIN The Journal of Cutaneous Medicine 6 (2): s2. https://doi.org/10.25251/skin.6.supp.2.